Literature DB >> 6410800

In vivo quantitation of regional cerebral blood flow in glioma and cerebral infarction: validation of the HIPDm-SPECT method.

B Drayer, R Jaszczak, A Friedman, R Albright, H Kung, K Greer, M Lischko, N Petry, E Coleman.   

Abstract

Iodine-123 labeled hydroxyiodopropyldiamine (HIPDm) is a diffusible indicator with an 85%-90% extraction fraction and stable retention in the brain for more than 2 hr. Equilibrium-phase imaging and quantitation using single-photon emission computed tomographic (SPECT) scanning defined a distribution of HIPDm in proportion to regional cerebral blood flow (rCBF). Studies in calves affirmed a close correspondence (r = 0.97) in calculated rCBF between HIPDm and microspheres using the tissue deposition-arterial input function microsphere methodology. Using this same mathematical analysis in vivo, reproducible rCBF data within the expected range of normal were obtained on repeated studies in the same nonhuman primate. With a diffuse encephalopathy secondary to subarachnoid blood, a bilaterally symmetric decrease in rCBF was present. A prominent focal decrease in HIPDm accumulation and calculated rCBF was noted with cerebral infarction in the distribution of a ligated middle cerebral artery. Patient studies with glioma revealed diminished HIPDm accumulation due to decreased flow and/or pH in the region of the neoplasm as well as in the associated vasogenic edema and overlying gray matter.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6410800      PMCID: PMC8334969     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  2 in total

1.  Neoplastic encephalopathy: dynamic CT of cerebral gliomata.

Authors:  J R Jinkins
Journal:  Neuroradiology       Date:  1988       Impact factor: 2.804

2.  Intra-arterial infusion of N-isopropyl-p[123I]iodoamphetamine for assessing effective blood supply to pulmonary and hepatic neoplasms.

Authors:  C Miyazaki
Journal:  Ann Nucl Med       Date:  1994-05       Impact factor: 2.668

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.